



NABL ACCREDITED ISO / IEC 17043:2010, PC-1033 / 27.12.2018

DECEMBER 2020

106th EQAS EVALUATION REPORT

MEMBER ID:

4

Marks Obtained:65.5/67(97.8%)

DECEMBER 2020 / BACTERIOLOGY SMEARS:

Question: Carry out the appropriate staining procedure and document the relevant observation. Please refer the attached evaluation format/answer template for details on the criteria for evaluation. Provide the Impression or probable organism seen (AS ASKED)

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been underlined in the expected report.

	3.5	ယ	Possible organism (1 mark): Corynebacterium spp	days.	
211)		Gram positive bacilli in palisade arrangement.	and fever and malaise for 2	
2.5	2	1.5	slender club bacilli arranged Chinese letter pattern (1) along with four	specimen of a 6-year old child	
	0.5	0	Ų.	on the given fixed smear prepared from a THROAT	
			Presence of host cells & debris (1mark); No pus cells	Please carry out a Gram stain	SM2
0 0	(3.5)	w	о примения рисипопии	for one day.	,
)		Probable organism (1 mark): Strentagaggers magning	fever, headache and vomiting	
2.5	2	1.5	lanceolate shaped diplococci (1)	presenting with high grade	
			Description of Organism/s (2marks): Many (0.5) Gram positive (0.5)	prepared from a CSF specimen	
	0.5	0	rresence of nost cells & debris (Imark): Few pus cells	on the given fixed smear	
				Please carry out a Cuam stain	SMI
	Evaluation	Eva	Expected Report	se Question er	Number
				South Charles and Charles	T-

						SM3
	days.	frequency and urgency for 2	-year-	prepared from a voided	on the given fixed smear	Please carry out a Gram stain
Candida Spp	Possible organism (1 mark): Candida spo	oval yeast like organisms with pseudohyphae (1)	Description of Organism/s (2 marks): Many (0.5) Gram positive (0.5)		cells	Presence of host cells & debris (Imark). Few nine cells Few acids it.
w		1.5		0		
3.5		2		0.5		
(4)		2.5		_		

DECEMBER 2020 / BACTERIOLOGY CULTURE:

techniques for each exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given Question: A freeze-dried (lyophilized) culture of an organism isolated from a clinical specimen is given. Carry out the appropriate

Please refer the attached evaluation format for details on the criteria for evaluation.

A 'partially correct' or 'incorrect' component of the participant report which has resulted in a deduction of marks has been in indicated

CU 1: Isolated from a BLOOD culture of a 58-year-old diabetic admitted with fever and chills for 2 days following a lower urinary tract

FINAL INDENTIFICATION: Klebsiella aerogenes

stain + Motility) biochemical findings enabling final aracteristics)		NOT EVALUATED		
Reported Not reported	1 2 3(1)			(Minimum 3 key characteristics) Final identification
ain + Motility) Keported Not reported			•	Salient culture and biochemical findings enabling final identification
Reported Not reported	0 0.5(1)		<	
	Evaluation (7 marks	Not reported	Keported	Microscopy (Gram stain + Mastite)

			>23	Tazobactam ≤17 ≥128/4	Pinero:III: ≥17 ≤16	Amikacin ≥15 ≤4	Gentamicin ≤19 (lg/ml)	Cone size (mm)	Susceptibility report EXPECTED REPORT
	A	Suscentible	,	Resistant	Suscentible	Susceptible	Resistant	pretation	
							Incorrect	FARTICIPANT REPORT	0
(-1 0 1(2)		-1 0 1(2)	-1 0 1(2)	-1 0 1(2)	-1 0 1(2)	10 marks	MARK	
	mE/ ME/ VME		mE/ ME/ VME	mE/ME/VME	mE/ME/VME	mE/ME/VME	Error	довия до закл.	

CUZ	1
2: Is	
olate	
d fro	
m a l	
RI	
E sp	
ecim	
en of	
a 36	
nen of a 36-year	
plo.	
gent	
emai	
wit	
6-year old gentleman with renal	
0	
alculi	

FINAL IDENTIFICATION: Morganella morganiii

Microscopy (Gram stain + Motilian)	Reported	Not reported	Evaluation (7 marks)
Salient culture and bigg.	<		0 0.5(1)
identification	<		
(Minimum 3 key characteristics))
Final identification			1 2 3(4)
2	<		0 05 1 150

report		EATECTED REPORT	KEPOKI	PARTICIPANT REPORT	T REPORT	MARK	TVDF OF FRACE
	Zone size	MIC	Interpretation	Comme			TIPE OF ERROR
	(mm)	(μg/ml)		Correct	Incorrect	10 marks	Eme
Cefpodoxime*	•	¥	Danistant	The state of the s			
-		1,5	Resistant	<	0.000		
Ciprofloxacin	521	⊻	Desistant			<u>.</u>	mE/ ME/ VME
			Tresistant	<		1010	
Amikacin	≤14	<u>%</u>	Resistant		5	3.6	mE/ME/VME
Pineracillia				•		-1010	TE ME LINE
Toront	1/	2128/4	Resistant			(THE MINE AME
razobactam						1010	mE/ME/VME
Meropenem	<19	¥	Darit	*		(THE MEY AME
			VESISIAII	<		1010	
cerpodox	ame Disk Diffusi	on testing not to	cerpodoxime Disk Diffusion testing not to be done for March 11		The form of the second of the second		ME/ ME/ VME

CU3: Isolated as the predominant organism from an EXUDATE specimen of a left lower limb ulcer from a 63-year-old diabetic woman. FINAL IDENTIFICATION: *Proteus mirabilis*

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	<		0 0.5(1)
Salient culture and biochemical findings enabling final	<	ert z	1 2 3(4)
identification			(
(Minimum 3 key characteristics)			
Final identification	<	Signal Section	0 0.5 1 1.5 (2)

Susceptibility		EXPECTED REPORT	REPORT	PARTICIPA	PARTICIPANT REPORT	MARK	TYPE OF ERROR
report	Zone size	MIC (ug/ml)	Interpretation	Correct	Incorrect	10 marks	Error
	(mm)	(µg/ml)	The state of the s	A CONTRACTOR SERVICE AND A SER	Control of the Contro		
Co-trimoxazole	≥16	≤2/38	Susceptible	<		-1 0 1 (2)	mE/ME/VME
Levofloxacin	≥21	≤0.5	Susceptible	<		-1 0 1(2)	mE/ME/VME
Piperacillin-	≥21	≤16	Susceptible	< <		-1 0 1(2)	mE/ME/VME
Tazobactam							-E/ME/VME
Ertapenem	≥22	≤0.5	Susceptible	<		-1 0 1	\neg
Meropenem	≥2.3	≤1.0	Susceptible	<u> </u>		-1 0 1 2	mE/ ME/ VME

DECEMBER 2020 / SEROLOGY

the attached evaluation format/answer template for details on the criteria for evaluation.

_	_	_	_	_	_	_	_	-	_		•
	SE3		SE2		1	SEI					3
	CRP		WIDAL*		1	RA			Parameter		lease refer th
	Positive		Correct Correct		0	Negative			Result	Your	e attached
	62.7				IU/mL	1011	18.1		Value	Your	CVAIUALIOII
		200	Negative	STO							IOI IIIavaii
	Positive	0	Negative	STH		Negative			Result	Intended	Street termp
	⁄e		Negative Negative Negative	STH Interpretation		ve				Ä	Flease refer the attached evaluation for manager complete some
	(n-330) 60.0593 10.4500 199.9 Provider (PTP).	Turhidimetry	aggiutiliation	Since	Critic	(n-245)	Turbidimetry	The Charles of the September of the Charles of the		nomatri	Mathad
Lind Lind	60.0593					0.000	85528	The state of the s	Mean	Robust Robust	
Proficien	10.4500	10 4066		Not Applicable			4.1086	1000	2		
EA Teams	199.9	0.00.0	24 90 0	icable		31.200	21.260			(mg/L) Z'	Range
	Provide	ე კ					2.3		score		Z &
	r (PTP).	2	,	•	J		7	,	11200	Marks Score	
			٠		2		1.0	h	The Part of the Pa	Score	V

RA: Rheumatoid Factor, CRP: C-reactive Protein. NA: Not Applicable. *Expected value is determined by the Proficiency

Page 4 of 5

<u>Disclai</u> This is a

Disclaimer:

;smolloj

mol Bair b Izsi ədi

id

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID:

Z
0
9
1
4

. 13 17 1	4 4 4 15	Spinister Comment
2	1.5	
2	2	
2	2	CHO
Maximum	65.5	Marks obtain
1 marks = 67	97.8%	obtained

Scientific Co-ordinator Dr. Rani Diana Sahni

Quality Manager Dr. John A Jude Prakash

🔊 Dr. V. Balaji PT Co-ordinator

Report Dispatch Date: 28.02.2021

************** End of Report ***********

Scanned with CamScanner



RML – Quality Assurance Program (RML – QAP)



Lab Code No.

2083

BASIC SEROLOGY FINAL RESULT ASSESSMENT

CYCLE NO.: 10

ROUND: 2

TOTAL PARTICIPANT: 266

DATE: 30/03/2021

Total Responses	Your Result	All Lab Result	%	Remarks
-				
234	Non-Reactive	Reactive : 0 Non-Reactive : 234	100%	Within Consensus
226	Negative	Positive: 8 Negative: 218	96%	Within Consensus
	0/	0/	Non-Reactive Non-Reactive : 234 Negative Positive : 8	Non-Reactive Reactive : 234 Non-Reactive : 234 Negative Positive : 8

Chief Coordinator

Son

Dr. Sanjay Mehrotra

Checked By:

Programme Director

Dr. Bandana Mehrotra

End of Report

Page 1 of 1



Address: B-171, Nirala Nagar, Lucknow - 226 020. Ph.: 4034100-130 (30 Lines). 4077180, 2788444 Fax: (0522)2788555

Email: rmlresearchfoundation@gmail.com Website: www.rmlpathology.com

Continuous Efforts And Execution Leads To Quality Excellence



RML – Quality Assurance Program (RML – QAP)



To,

Date: 09.01.2021

Sr. Aruna. St. Theresa's Laboratory Opposite Erragadda Rythu Bazar Sanath Nagar, Hyderabad, Telangana- 500018

Subject: RML Quality Assurance Program 2021-Cycle-Ten (10)

Dear Participant,

We confirm your enrollment in our Quality Assurance Program Cycle-10, 2021. Mentioned below are some important details.

- 1. Your Lab Confidential Code is 2083
- 2. Field you opted for
- a) Urine Routine
- b) Basic Sero-01
- 3. You are requested to mention only your Lab Code while submitting the results which can also be mailed to us at rmlresearchfoundation@gmail.com clearly mentioning your lab code in subject line.
- 4. Sample dispatch will have prior information.
- 5. If you have not received the sample within 5 days of dispatch or there is any discrepancy in the sample received. Kindly send an email urgently. So that corrective action can be taken.
- 6. Please adhere to mentioned time lines.

"QAP program success is dependent on your cooperation"

Chief PT Coordinator

(Dr., Sanjay Mehrotra)



Address B 17 Nirata Nagai Fucknow 226 020 Ph.: 4034100-130 (30 Lines): 4077180 2788441 Fax (0522)2788555

Lin militescarchfoundation@gmail.com Website www.rmlpathalogy.com